Rhythm Pharmaceuticals, Inc.
RYTM
Rangering i aksjer
#3014
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Aksjekurs
$88.37
Sist synkronisert: 2026-10-19
Markedsverdi
$6.08B
Endring (1 dag)
2.55%
Endring (1 år)
-21.37%
Land
US
Handel Rhythm Pharmaceuticals, Inc. (RYTM)
Kategori
Healthcare
P/B-forhold for Rhythm Pharmaceuticals, Inc. (RYTM)
P/B-forhold per October 2026 TTM: 27.37
Ifølge Rhythm Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 27.37. Ved slutten av 2023 hadde selskapet et P/B-forhold på 15.62.
P/B-historikk for Rhythm Pharmaceuticals, Inc. fra 2012 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 27.37 | 31.91% |
| 2024 | 20.75 | 32.87% |
| 2023 | 15.62 | 171.92% |
| 2022 | 5.74 | 229.68% |
| 2021 | 1.74 | -77.89% |
| 2020 | 7.88 | 164.74% |
| 2019 | 2.98 | -12.07% |
| 2018 | 3.38 | -36.92% |
| 2017 | 5.36 | -92.20% |
| 2016 | 68.78 | 619.55% |
| 2015 | 9.56 | -101.12% |
| 2014 | -854.44 | 3,155.60% |
| 2013 | -26.25 | -36.85% |
| 2012 | -41.56 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | -77.16% |
US
|
|
| 13.2547 | -51.57% |
US
|
|
| 4.208 | -84.63% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -77.41% |
NL
|
